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A B S T R A C T
Background
During acute and early HIV-1 infection (AEI), up to 60% of CD4þ T cells in the lamina propria
of the lower gastrointestinal (GI) tract are lost as early as 2–4 wk after infection. Reconstitution
in the peripheral blood during therapy with highly active antiretroviral therapy (HAART) is well
established. However, the extent of immune reconstitution in the GI tract is unknown.
Methods and Findings
Fifty-four AEI patients and 18 uninfected control participants underwent colonic biopsy.
Forty of the 54 AEI patients were followed after initiation of antiretroviral therapy (18 were
studied longitudinally with sequential biopsies over a 3-y period after beginning HAART, and
22 were studied cross sectionally after 1–7 y of uninterrupted therapy). Lymphocyte subsets,
markers of immune activation and memory in the peripheral blood and GI tract were
determined by flow cytometry and immunohistochemistry. In situ hybridization was performed
in order to identify persistent HIV-1 RNA expression. Of the patients studied, 70% maintained,
on average, a 50%–60% depletion of lamina propria lymphocytes despite 1–7 y of HAART.
Lymphocytes expressing CCR5 and both CCR5 and CXCR4 were persistently and preferentially
depleted. Levels of immune activation in the memory cell population, CD45ROþ HLA-DRþ,
returned to levels seen in the uninfected control participants in the peripheral blood, but were
elevated in the GI tract of patients with persistent CD4þ T cell depletion despite therapy. Rare
HIV-1 RNA–expressing cells were detected by in situ hybridization.
Conclusions
Apparently suppressive treatment with HAART during acute and early infection does not lead
to complete immune reconstitution in the GI mucosa in the majority of patients studied,
despite immune reconstitution in the peripheral blood. Though the mechanism remains
obscure, the data suggest that there is either viral or immune-mediated accelerated T cell
destruction or, possibly, alterations in T cell homing to the GI tract. Although clinically silent
over the short term, the long-term consequences of the persistence of this lesion may emerge
as the HIV-1–infected population survives longer owing to the benefits of HAART.
The Editors’ Summary of this article follows the references.
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Introduction
Over the past 25 y, more than 25 million individuals have
succumbed to the complications of HIV-1 infection [1]. The
development and evolution of highly active antiretroviral
therapy (HAART) has resulted in the ability to achieve
durable control of viral replication and preservation of
immune function in the majority of treated patients with
relatively simple and minimally toxic treatment regimens [2–
7]. Recent ﬁndings suggest that immune parameters meas-
ured in the peripheral blood of patients infected with HIV-1
may not be representative of the immune system as a whole,
particularly when considering the status of the less well
characterized, but far more sizeable mucosal immune system
[8–11].
During acute and early HIV-1 infection (AEI), there is
selective depletion of CD4þ T cells in the gastrointestinal (GI)
lamina propria (LP) compared with levels measured in the
peripheral blood [10–12]. Our studies have suggested that up
to 60% of LP CD4þ T lymphocytes are lost as early as 2–3 wk
into the course of infection. This is likely due to the presence
of densely clustered CCR5þ memory CD4þ T cells [13–15] at
mucosal sites that serve as preferred targets for HIV-1
infection.
These ﬁndings have reignited interest in the impact of
HAART on CD4þ T cell reconstitution in the GI tract
compared with the peripheral blood. Guadalupe et al. have
reported that of two patients treated during primary HIV-1
infection, near-complete mucosal reconstitution occurred in
one patient, whereas the second patient showed incomplete
restoration despite 5 y of antiretroviral therapy [12]. The
same group concluded from the study of simian immunode-
ﬁciency virus (SIV)–infected macaques that CD4þ T cell
reconstitution could be achieved to near-complete levels in
the GI tract if antiretroviral therapy was initiated during
primary SIV infection but not if therapy was started later in
infection [16]. Our initial description of eight patients
studied cross sectionally 6 mo to 5 y after the initiation of
therapy during acute and early infection suggested that
despite therapy, CD4þ T cell depletion persisted in the GI
mucosa [11]. Thus, there are somewhat conﬂicting and
limited data on the reconstitution of the GI immune system
with potent antiretroviral therapy, particularly when treat-
ment is initiated during AEI. Given that the GI tract harbors
the largest collection of immune cells in the body, it is critical
to assess this compartment for immune reconstitution with
antiretroviral therapy.
To address this issue conclusively, we undertook the
present study. Our aims were: (1) to determine the effect of
uninterrupted antiretroviral therapy initiated during AEI on
the reconstitution of GI mucosal T-lymphocyte population;
(2) to examine the phenotype of mucosal lymphocytes prior
to and during long-term antiretroviral therapy; and (3) to
examine clinical, immunological, and virological factors
involved in the reconstitution of the GI immune system
during antiretroviral therapy. We prospectively followed 18
individuals identiﬁed and treated during AEI, and performed
recto-sigmoid colonic biopsies on these individuals prior to
treatment and serially up to 32 mo following the initiation of
treatment. In addition, we extended our cross-sectional
colonic biopsy studies to include a total of 22 individuals
who were also treated during acute and early infection. We
therefore examined a relatively large cohort of patients, all
treated during AEI, to determine whether CD4þ T cell
numbers reconstitute to the same extent in the GI tract as
observed in the peripheral blood. An additional 14 individ-
uals with AEI provided biopsy specimens only prior to
treatment.
Methods
Patients and Sample Acquisition
Peripheral blood and recto-sigmoid colonic mucosal tissue
were collected from HIV-1–infected patients and HIV-1–
uninfected control participants. Informed consent was
obtained from all patients and the study was approved by
the Institutional Review Boards of the Rockefeller University,
Bellevue Hospital Center (New York, New York, United
States), and Manhattan Veteran’s Administration Hospital
Center (New York, New York, United States). All clinical
investigation was conducted according to the principles
expressed in the Helsinki Declaration.
Endoscopic biopsies were obtained from macroscopically
normal colonic mucosa and were processed as described
previously [11]. Brieﬂy, the biopsies were taken using large-
cup endoscopic-biopsy forceps (Microvasive Radial Jaw,
Boston Scientiﬁc, Boston, Massachusetts, United States)
(outside diameter 3.3 mm) and (1) placed immediately in
tissue-culture medium (RPMI 1640, Mediatech, Herndon,
Virginia, United States); (2) placed into 2-ml pre-labeled
cryovials (Nalgene, Rochester, New York, United States) and
frozen in liquid nitrogen; or (3) placed in formalin to
preserve tissue architecture. Formalin-ﬁxed tissues were
washed with phosphate-buffered saline (PBS), transferred to
100% alcohol and processed for immunohistochemistry and
in-situ hybridization. Phlebotomy was undertaken immedi-
ately prior to endoscopy.
Immediately after acquisition, mucosal mononuclear cells
(MMCs) were enzymatically isolated from mucosal biopsies
using a 30-min incubation in collagenase type II (Clostridio-
peptidase A, Sigma-Aldrich, St. Louis, Missouri, United
States) followed by mechanical separation through a blunt-
ended 16-gauge needle. The digested cell suspension was
strained through a 70-lm disposable plastic strainer. Imme-
diately after isolation, cells were washed with PBS and
resuspended in PBS containing antibodies for ﬂow cytometry.
Peripheral blood mononuclear cells (PBMCs) were prepared
by centrifugation on a Ficoll-Hypaque density gradient
(Mediatech). PBMCs were stained for ﬂow cytometry imme-
diately after isolation.
Flow Cytometry
Cell surface expression of lymphocyte antigens was
identiﬁed by monoclonal antibody staining of freshly isolated
MMCs and PBMCs, followed by ﬂow cytometry using a
FACSCalibur (Becton-Dickinson, Palo Alto, California,
United States) with analysis using CellQuest software (Bec-
ton-Dickinson). Monoclonal antibodies used in this study
included: anti-human CD3-ﬂuorescein isothiocyanate (FITC)
(clone UCHT1) (Becton-Dickinson), anti-human CD3-phy-
coerythrin (PE) (clone SK-7) (Becton-Dickinson), anti-human
CD3-peridinin chlorophyll-a protein (PerCP) (clone SK-7)
(Becton-Dickinson), anti-human CD4-allophycocyanin (clone
RPA T4) (PharMingen, San Diego, California, United States),
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anti-human CD8 PE (clone RPA T8) (PharMingen), anti-
human CXCR4-PE (clone 12G5) (PharMingen), anti-human
CCR5-FITC (clone 2D7/CCR5) (PharMingen), anti-human
HLA-DR PerCP (clone L243, BD Biosciences Pharmingen,
San Diego, California, United States), anti-human CD45RO
PE (clone UCHL1, BD Biosciences Pharmingen), anti-human
Ki67 FITC (clone B56, BD Biosciences Pharmingen), anti-
human CCR7 PE (clone 3D12, BD Biosciences Pharmingen),
anti-human CD62L allophycocyanin (clone Dreg56, BD
Biosciences Pharmingen), and the appropriate isotype con-
trols. During ﬂow cytometry, lymphocytes, initially identiﬁed
by their forward- and side-scatter characteristics, were
subject to phenotypic analysis. Dead cells were excluded
from analysis using 7-aminoactinomycin D [17] (Calbiochem,
San Diego, California, United States).
To determine the percentages of CD4þ and CD8þ cells in
the T cell population, gated lymphocytes were initially
examined for the expression of CD3. The CD3þ lymphocytes
were then analyzed for expression of CD4 and CD8 receptors.
To evaluate the expression of chemokine co-receptors, gated
lymphocytes were initially examined for the expression of
CD4 receptors. The CD4þ lymphocytes were further exam-
ined for the expression of chemokine co-receptors CCR5 and
CXCR4. To examine for activated memory cells, gated CD4þ
and CD8þ lymphocytes were examined for the expression of
CD45RO and HLA-DR. Central and effector memory cells
were evaluated by the expression of CD62L and CCR7 on
gated CD4þ and CD8þ lymphocytes.
Light Microscopy and Immunohistochemistry
All immunohistochemistry and in-situ hybridization sec-
tions were examined independently by two board-certiﬁed
pathologists with signiﬁcant experience in the ﬁeld.
For light-microscopic evaluation, tissues were ﬁxed in 4%
neutral-buffered formalin and embedded in parafﬁn. Sec-
tions (of 5 lm thickness) were cut and stained with
hematoxylin-and-eosin and Giemsa stains. Immunohisto-
chemistry was also performed on parafﬁn-embedded sections
after high-temperature antigen retrieval as described pre-
viously [18]. Brieﬂy, the sections were de-waxed and antigen
retrieval was performed by pressure cooking the sections for
3 min in 50 mM Tris and 2 mM EDTA (pH 9)—for CD4, or 3
min in 0.01 M buffered sodium citrate solution (pH 6)—for
CD8. The sections were cooled to room temperature and
rinsed in Tris-buffered saline (pH 7.4). The sections were
incubated with 1:25 dilution of antibody to CD4 (NCL-CD4-
IF6, Novocastra Laboratories, Newcastle-upon-Tyne, United
Kingdom) or to 1:100 dilution of antibody to CD8 (C8/144B,
DakoCytomaton, Glostrup, Denmark) for 60 min, followed by
incubation with a 1:20 dilution of rabbit anti-mouse
secondary antibody (DakoCytomaton code 259) for 20 min.
The tertiary antibody (APAAP-Complex Monoclonal Mouse,
DakoCytomaton) was applied in 1:50 dilution. The incuba-
tions were carried out at room temperature and were
followed by rinsing in Tris-buffered saline (pH 7.4) for 5
min each. The alkaline phosphatase was revealed by New
Fuchsin as the chromogen.
CD4þ or CD8þ cells in the LP (effector site) and the
organized lymphoid tissue (OLT) (inductive site) were
quantiﬁed separately. Using a 403 objective, a standard area
was set (unit area), and a photomicrograph was taken with a
Zeiss AxioImager M1 microscope equipped with AxioCam
MRc5 digital camera (Zeiss, Jena, Germany). Fifteen non-
overlapping unit areas were selected for the LP, and between
two and ﬁve unit areas were selected for the OLT, depending
upon the size of the T-dependent zone. Using AxioVision
(Release 4.5) software (Zeiss), positive cells showing lympho-
cyte morphology were counted. Because macrophages and
dendritic cells also express CD4 in high intensity, manual
counting was chosen instead of automatic measurement.
Owing to technical reasons (high background signal, lack of
adequate material, inadequate staining, etc.), data were
available only on 30 out of the 40 patients.
Immunohistochemical Double Labeling for Detection of
Proliferating T Cells
After heat-mediated antigen retrieval by pressure cooking
(3min in 50mMTris and 2mMEDTA [pH9]), the sections were
incubated with anti-CD4 or CD8 antibodies overnight as
described above. Immunodetection was performed either with
the StreptABComplex/HRP (Code K0391, DakoCytomaton)
using 3-amino-9-ethylcarbazole (Sigma-Aldrich) as the sub-
strate or with APAAP (DakoCytomaton) and Fast Blue as
chromogen. The sections were then heat-treated again for 5
minwith 0.01M buffered sodium citrate solution (pH 6.0). This
was followed by an overnight incubation withMIB-1 (anti-Ki67
antibody, DakoCytomaton). For the second antibody, either
the APAAP (DakoCytomaton) or the StreptABComplex/HRP
(DakoCytomaton) visualization system was applied.
In Situ Hybridization
The in situ hybridization was performed on parafﬁn
sections as described previously [18]. A 35S-labeled, single-
stranded anti-sense RNA probe of HIV-1 (Lofstrand Labo-
ratories, Gaithersburg, Maryland, United States), composed
of fragments of 1.4–2.7 kb, which collectively represent
approximately 90% of the HIV-1 genome [19], was used.
Multiple sections (4–28) were examined in the treated cases to
detect the presence of HIV-1 RNA–expressing cells.
Semiquantitative Analysis of the HIV-1 RNA–Positive Cells
The autoradiographs were examined with a microscope
equipped with epiluminescent illumination (Axiophot, Zeiss),
a 3CD camera, and a PC-based image-analysis system (KS
4000, Kontron, Esching, Germany) as described previously
[11]. Brieﬂy, cells were considered positive for viral gene
expression if the grain count was more than six times that of
the background. The positive cells were counted. The area
occupied by lymphoid follicles was measured, and the
frequency of RNA-producing cells per mm2 of tissue was
calculated. To evaluate the number and distribution of T cell
subsets, transmission light was used. Using a 403 objective, a
standard area was set by the image analyzer. The number of
positive cells within this unit area was determined by manual
counting. For the LP, a total of 10–15 consecutive non-
overlapping ﬁelds were analyzed for each staining. For the
OLT, between two and ﬁve representative areas were chosen.
The individual values obtained with each T cell marker were
then pooled, and the mean numbers of positive cells per unit
area of LP or OLT were determined separately.
Statistical Methodology
Values are expressed as mean 6 standard deviation.
Statistical comparisons were made between PBMCs and
MMCs from individuals using a paired t-test. Statistical
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comparisons were made between HIV-1–infected patients
and control participants using a two-sample, unequal
variance t-test. All reported p-values were two-sided at the
0.05 signiﬁcance level using SPSS 11.0 for Windows software
(SPSS, Chicago, Illinois, United States).
Results
Baseline Characteristics of Study Patients
A total of 54 patients with AEI and 18 HIV-1–uninfected
control participants were studied. Of the HIV-1–infected
patients, biopsies were performed on 32 individuals during
AEI prior to initiation of antiretroviral therapy. Of these 32
patients, 18 were followed longitudinally post–antiretroviral
therapy initiation with recto-sigmoid biopsies at 1 y (n¼ 5), 2
y (n ¼ 9), and 3 y (n ¼ 4). An additional 22 patients were
studied cross sectionally after initiation of HAART for up to
1 y (n ¼ 7), 2 y (n ¼ 7), and 3–7 y (n ¼ 8) (Table 1). On
presentation, patients were all viremic and were staged as per
the National Institutes of Health (NIH)–sponsored Acute HIV
Infection and Early Disease Research Program: enzyme
immunoassay (EIA)–negative (stage Ia), Western blot inde-
terminate (stage Ib), a nonreactive detuned EIA [20] with an
optical density (OD) value of less than 0.5 or a documented
negative EIA within 3 mo of presentation (stage II), and a
nonreactive detuned EIA (OD 0.51–1.0) or a documented
negative serology within 6 mo of presentation (Stage III).
During AEI, all patients had initiated therapy that comprised
combinations of nucleoside (nucleotide) reverse transcriptase
inhibitors with either a protease inhibitor and/or a non-
Table 1. Patient Characteristics
Cohort Patient
Number
At Presentation
Duration of
Treatment (mo)
Posttreatment
Stage CD4þ T Cell Counts
(Cells/mm3)
CD8þ T Cell Counts
(Cells/mm3)
Log10 Viral Load
(Copies/ml)
CD4 Counts
(Cells/mm3)
CD8 Counts
(Cells/mm3)
Longitudinal
cohort
102 Ia 391 312 7.1 32 1,093 709
100 II 595 1,259 5.5 31 885 561
106 Ia 368 874 5.4 31 718 753
103 II 538 721 3.8 30 736 659
336 II 556 1,368 5.0 29 708 446
109 II 340 803 6.3 30 582 441
119 Ia 350 1,354 6.3 25 628 727
122 III 400 1,086 5.0 27 772 512
125 II 684 855 5.0 24 788 585
127 Ia 350 1,075 5.0 23 344 1,047
131 Ia 250 959 6.8 25 903 818
137 Ia 178 1,325 6.0 20 390 494
347 Ia 291 679 4.4 19 280 265
141 III 489 1,146 4.9 16 556 786
142 II 330 575 4.2 16 657 668
143 Ia 442 621 5.2 16 774 394
146 II 391 633 4.5 14 500 715
147 Ia 194 267 6.0 12 821 490
Cross-sectional
cohort
64 Ia 846 2,657 5.8 12 994 1085
1309 III 457 469 3.9 11 451 363
78 II 175 577 7.4 12 370 701
327 II 572 614 4.1 12 840 652
340 Ia 556 1368 5.0 8 996 880
107 II 610 1,157 5.9 8 737 754
114 II 564 469 5.2 12 919 652
312 II 366 572 6.2 29 657 1013
56 II 619 409 5.4 25 644 255
81 Ia 252 779 5.4 20 551 557
85 II 592 2,148 5.2 24 865 652
63 Ia 449 1,257 5.5 29 881 413
75 Ib 258 378 7.3 28 740 689
77 II 575 1,221 5.3 28 1,106 993
106 III 351 2,234 6.3 44 595 761
133 III 627 542 4.2 37 1,168 743
87 Ia 395 1,574 5.3 38 766 893
154104 Ia 487 812 6.7 54 711 422
923 Ia 698 903 5.1 70 939 696
28 Ia 610 2,191 6.0 59 1,150 692
154131 Ia 286 970 5.0 44 374 455
63 II 777 1,013 5.0 79 1,128 813
Patients were staged as per the NIH-sponsored Acute HIV Infection and Early Disease Research Program as follows: EIA-negative (stage Ia), Western blot indeterminate (stage Ib), or a
nonreactive detuned EIA with OD, 0.5 or a documented negative EIA within 3 mo of presentation (stage II), a nonreactive detuned EIA (OD 0.51–1.0), or a documented negative serology
within 6 mo of presentation (Stage III).
doi:10.1371/journal.pmed.0040484.t001
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nucleoside reverse transcriptase inhibitor. Patients were
highly adherent to treatment and maintained undetectable
plasma viral loads during treatment. There were no signiﬁ-
cant differences between the longitudinal and cross-sectional
groups with respect to CD4þ T cell count on presentation,
log10 HIV-1 viral load on presentation, or the estimated
duration of infection on presentation. All were male patients
who had contracted HIV-1 sexually during same-sex contact.
The 18 HIV-1–uninfected control participants were re-
cruited from a population undergoing screening colonoscopy
at the time of study recruitment. This group comprised ten
men and eight women. None of the HIV-1–infected patients
or HIV-1–uninfected control participants were found to have
macroscopic evidence of GI mucosal disease, nor were any
concomitant pathological processes found on histological
examination. All enrolled patients and control participants
signed an informed-consent form that was approved by the
institutional review boards of the Rockefeller University,
Bellevue Hospital Center, and Manhattan Veteran’s Admin-
istration Hospital Center.
Reconstitution of CD4þ T Cells Is Incomplete despite
HAART
In order to study the effect of antiretroviral therapy on the
reconstitution of CD4þ T cells, we utilized ﬂow cytometry to
determine the percentage of CD4þ T cells in the GI tract and
peripheral blood (Figure 1A). Twenty-two HIV-1–infected,
treated patients were examined cross sectionally (where no
pre-ART biopsy was available) and were compared with HIV-
infected, untreated patients (AEI patients, n ¼ 32) and
uninfected control participants (n ¼ 18). In the uninfected
control participants, the mean PBMC CD4þ T cell percentage
was 59.6% 6 14.3% and the mean MMC CD4þ T cell
percentage was 56.4% 6 8.8%. In AEI patients, the mean
PBMC CD4þ T cell percentage was 41.5% 6 12.9% and the
mean MMC CD4þ T cell percentage was 19.3% 6 8.8%. In
patients treated for up to 1 y (n¼ 7), the mean PBMC CD4þ T
cell percentage was 46.9% 6 10.1% and the mean MMC
CD4þ T cell percentage was 27.8% 6 14.5%. In patients
treated for 1–3 y (n ¼ 7), the mean PBMC CD4þ T cell
percentage was 58.1% 6 12.3% and the mean MMC CD4þ T
cell percentage was 42.3% 6 3.1%. In patients treated for 3–
7 y (n ¼ 8), the mean PBMC CD4þ T cell percentage was
59.9% 6 12.0% and the mean MMC CD4þ T cell percentage
was 42.5% 6 13.6% (Figure 1B). Thus, based on ﬂow
cytometry, in the cross-sectional group, the percentage of
CD4þ T cells in the GI tract was signiﬁcantly lower than the
percentage of peripheral blood CD4þ T cells during AEI (p ,
0.001), and remained low after treatment for up to 1 y (p ,
0.001), 1–3 y (p ¼ 0.003), and 3–7 y (p ¼ 0.02).
Next, we sought to follow patients longitudinally to assess
the effect of antiretroviral therapy on the GI tract and
peripheral blood in each study participant. Of the 32 patients
that were examined during AEI, we followed 18 patients with
serial biopsies over a span of 3 y. Since patient recruitment
for repeated intestinal biopsies is challenging, enrolment in
the longitudinal group was limited to ﬁve out of 18 at year 1,
nine out of 18 at year 2, and four out of 18 at year 3 of
antiretroviral treatment. In each individual studied, the
percentage of CD4þ T cells remained signiﬁcantly lower in
the GI tract compared with the peripheral blood (Figure 1C).
When assessed as a group, the difference between PBMC and
MMC CD4þ T cell percentage was highly signiﬁcant after 1 y
(57.9% 6 11.9% CD4þ PBMCs versus 34.6% 6 4.2% CD4þ
MMCs; p , 0.001), 2 y (54.4% 6 10.9% CD4þ PBMCs versus
30.8% 6 9.8% CD4þ MMCs; p , 0.001), and 3 y (67.3% 6
9.8% CD4þ PBMCs versus 41.3% 6 4.9% CD4þ MMCs; p ¼
0.02) of suppressive antiviral therapy (Figure 1D). Thus, based
on ﬂow cytometry, the percentage of CD4þ T cells remained
signiﬁcantly lower in the GI tract compared with the
peripheral blood despite protracted antiretroviral therapy.
Immune-Inductive Sites Show Reconstitution with
Therapy, whereas Immune-Effector Sites Show Persistent
CD4þ T Cell Depletion
To corroborate ﬂow cytometry–derived data and to assess
for the absolute numbers of mucosal CD4þ T cells, immuno-
histochemistry was performed on parafﬁn-embedded biopsy
sections. Since CD4þ T cell depletion occurs preferentially in
the LP [11], we examined the immune-inductive sites
(represented by OLT) and effector sites (LP) for the effect
of antiretroviral therapy separately (Figure 2). All patients
(studied cross sectionally and longitudinally, data available on
30 out of 40 patients) are described in Figure 2. In HIV-
uninfected control participants, the mean CD4þ T cell count
was 229.6 6 24.6 cells/unit area in OLT and 11.0 6 3.3 cells/
unit area in LP. By comparison, mean CD4þ T cell counts in
the OLT were 212.5 6 63.8, 202.5 6 46.2, and 235.9 6 69.6
cells/unit area in the patients treated for up to 1 y, 1–3 y, and
3–7 y, respectively. However, in the LP, mean CD4þ T cell
counts statistically were highly signiﬁcantly depleted in all
groups—6.4 6 2.3 (p , 0.001), 6.5 6 1.6 (p , 0.001), and 7.8 6
2.6 cells/unit area (p¼ 0.004)—in the three treatment groups,
respectively. On examination of individual patients, nine
showed ‘‘normalization’’ (deﬁned as mean CD4þ T cells per
unit area in the LP of 18 HIV-uninfected control partic-
ipants—11.0 6 3.3 cells/unit area). The mean LP CD4þ T cell
count in these nine patients was 9.5 6 1.4 cells (p ¼ 0.13
compared with HIV-uninfected), the mean LP CD8þ T cell
count was 8.4 6 2.7 cells (p ¼ 0.3), and the mean CD4:CD8
ratio in the LP was 1.2 6 0.6 (p ¼ 0.07).
In the other 21 patients, persistent depletion of CD4þ T
cells was noted in the LP, with a mean CD4þ T cell count of
5.5 6 1.1 cells (p , 0.001). The mean CD8 T cell count in
these 21 ‘‘non-reconstitutors’’ was 8.0 6 1.7 cells (p¼ 0.3) and
the mean CD4:CD8 ratio was 0.7 6 0.1 (p , 0.001). Thus,
signiﬁcant depletion of the GI CD4þ T cell count persisted in
21 out of 30 (70%) of patients despite uninterrupted,
apparently suppressive, combination antiretroviral therapy.
As a corollary, in nine out of 30 (30%) of patients, the
absolute CD4þ T cell count per unit area reached HIV-
uninfected levels with treatment.
CCR5þ and CCR5þ/CXCR4þ CD4þ T Cells in the GI Tract
Remain Depleted Despite Therapy
Since a majority of the viruses during AEI are CCR5-tropic
[21], and a signiﬁcant proportion of cells in the GI tract
express CCR5 [13,14], depletion of CCR5-expressing cells is
observed preferentially in the GI tract during AEI [11,12]. We
wanted to assess the impact of antiretroviral therapy on the
reconstitution of CD4þ T cells expressing chemokine recep-
tors. Using four-color ﬂow cytometry, we quantiﬁed the
percentage of CD3þ/CD4þ MMCs that expressed CCR5 or
CXCR4, or co-expressed CCR5 and CXCR4 (Figure 3) in all
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Figure 1. Persistent Depletion of CD4þ T cells in the GI Tract despite Normalization in the Peripheral Blood
PBMCs and MMCs from 54 patients with AEI and 18 HIV-1–uninfected control participants were analyzed by flow cytometry. CD3þ gated lymphocytes
were analyzed for the expression of CD4 and CD8.
(A) Representative flow plots from patient 336 are depicted. CD8þ T cells are shown on the x-axis and CD4þ T cells on the y-axis.
(B) A box plot depicting the comparison between CD4þ T cells derived from the blood and GI tract of 22 patients examined cross sectionally. The
percentages of CD4þ T cells in the blood (white) and GI tract (grey) are compared between HIV-uninfected, AEI-untreated, and AEI groups treated for up
to 1 y, 1–3 y, and 3–7 y, respectively. In these plots, the boxes extend from the first to the third quartiles, enclosing the middle 50% of the data. The
middle line within each box indicates the median of the data, whereas the vertical line extends from the 10th to the 90th percentile. Means of the data
are represented by filled-in squares.
(C) Comparisons between the blood and GI tract of 18 patients followed longitudinally after initiation of antiretroviral therapy. The percentages of CD4þ
T cells in the blood (grey) and GI tract (black) at baseline (AEI-untreated) and following treatment are depicted per study patient.
(D) Cumulative data from the 18 patients followed longitudinally where the percentages of CD4þ T cells in the blood (white) and GI tract (grey) are
compared after 1 y, 2 y, and 3 y of HAART.
doi:10.1371/journal.pmed.0040484.g001
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Figure 2. Effector Sites (LP) of the GI Tract Showing Persistent CD4þ T Cell Depletion during HAART
Immunohistochemical characterization of immune-inductive and effector sites in rectal biopsies. Using a PC-based image-analysis system (KS 4000,
Kontron) a standard area was set by the image analyzer. For the LP, a total of between ten and 15 consecutive nonoverlapping fields were analyzed for
each staining. For the OLT, between two and five representative areas were chosen.
(A) CD4þ T cells per unit area were determined in OLT (left panel) and LP (right panel). Mean CD4þ T cell numbers were compared between HIV-
uninfected (white boxes), AEI (light grey boxes), and patients treated for up to 1 y (hatched boxes), 1–3 y (speckled boxes) and 3–7 y (dark grey boxes).
In these plots, the boxes extend from the first to the third quartiles, enclosing the middle 50% of the data. The middle line within each box indicates the
median of the data, whereas the vertical line extends from the 10th to the 90th percentile. Means of the data are represented by filled-in squares.
(B) A biopsy section (viewed at 403magnification) from an HIV-uninfected control participant, showing CD4þ T cells (stained red) within the GI LP (panel
I). In contrast, a pronounced reduction in LP CD4þ T cells is noted in a patient with AEI (patient no. 131) in panel II which does not correct despite
antiretroviral therapy for 2 y in the same patient (panel III). Another representative study patient (no. 142) is presented, where LP CD4þ T cell depletion
during AEI (panel IV) does not correct after antiretroviral therapy for 1 y (panel V).
doi:10.1371/journal.pmed.0040484.g002
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patients (followed longitudinally and cross sectionally on
HAART, n ¼ 40). Comparisons were made between HIV-
uninfected control participants, AEI, AEI treated for up to 1
y, AEI treated for 1–3 y, and AEI treated for 3–7 y. In the HIV-
uninfected patients, 78.8% 6 10.3% CD4þ T cells expressed
CXCR4, 68.4% 6 18.9% expressed CCR5, and 52.4% 6
12.4% co-expressed CXCR4/CCR5. As reported previously
[11], depletion in AEI untreated patients was noted in CD4þ
MMCs expressing CXCR4 (59.7% 6 20.0%, p¼ 0.04), more so
in CD4þCCR5þ T cells (39.0% 6 20.0%, p ¼ 0.002), and the
most signiﬁcantly in CD4þ MMCs dually expressing both
CCR5 and CXCR4 chemokine receptors (17.4% 6 14.2%, p ,
0.001).
Despite antiretroviral therapy, signiﬁcant depletion per-
sisted in the CD4þCCR5þ and CD4þ dual-positive MMCs,
when compared with HIV-uninfected patients. Speciﬁcally,
CD4þCCR5þMMCs in patients treated for up to 1 y (48.6% 6
14.7%, p ¼ 0.01), 1–3 y (45.7% 6 19.4%, p ¼ 0.01), and 3–7 y
(44.7% 6 17.6%, p ¼ 0.01) remained depleted. Similarly,
though more prominently, levels of CD4þCCR5þ/CXCR4þ
MMCs were lower in patients treated for up to 1 y (20.8% 6
8.4%, p , 0.001), 1–3 y (26.6% 6 15.8%, p¼ 0.001), and 3–7 y
(24.4% 6 13.8%, p , 0.001), respectively.
Activated Memory CD4þ and CD8þ T Cells Remain
Elevated in the GI Tract during HAART
HIV-1 infection results in a signiﬁcant increase in cellular
activation, which has been shown to be of prognostic value in
predicting the rate of CD4þ T cell decline without therapy
[22–24]. We wanted to understand the impact of cellular
activation at baseline and following treatment on the
reconstitution of CD4þ and CD8þ T cells in the GI tract and
peripheral blood. Using four-color ﬂow cytometry, we
assessed CD3þCD4þ and CD3þCD8þ lymphocytes for the
expression of CD45RO, a marker of immunological memory,
and HLA-DR, a marker of immunological activation.
It is well established that a majority of mucosal cells
(.90%) have a memory (CD45ROþ) phenotype [15]. Con-
sistent with this ﬁnding, we observed that 92.1% 6 10% of GI
CD4þ T cells were CD45ROþ in HIV-uninfected control
participants. In patients with untreated AEI, the percentage
of GI CD4þCD45ROþ T cells showed only a modest reduction
to 86.3% 6 12%, p ¼ 0.17 despite a well-documented,
profound depletion of the total number of GI CD4þ T cells.
Thus, the relative percentage of memory cells in the GI tract
remained stable despite an overall reduction in the total
number of CD4þ T cells. To examine the levels of cellular
activation, we examined memory (CD45ROþ) lymphocytes for
the expression of HLA-DR.
In the HIV-uninfected control part ic ipants ,
CD8þCD45ROþHLA-DRþ PBMCs represented 4.8% 6 3.9%
of the population and CD8þCD45ROþHLA-DRþ MMCs
represented 19.8% 6 9.8% of the population. In comparison,
during AEI, a signiﬁcant increase in CD8þCD45ROþHLA-DRþ
PBMCs (29.6% 6 19.5%, p , 0.001) and CD8þCD45ROþHLA-
DRþMMCs (47.57% 6 16.8%, p , 0.001) was noted. After 1 y
of treatment, the percentage of CD8þCD45ROþHLA-DRþ
PBMCs remained elevated (15.9% 6 12.1%, p ¼ 0.006) but
approximated HIV-uninfected levels in the 1–3 y treated
(4.9% 6 2.9%, p ¼ 0.9) and 3–7 y treated groups (5.7% 6
3.6%, p ¼ 0.5). In contrast, in the GI tract, the percentage of
CD8þCD45ROþHLA-DRþ MMCs remained elevated despite
Figure 3. CD4þ T Cells Expressing CCR5 and CCR5/CXCR4 Are Preferentially Depleted from the GI Tract during HAART
CD3þ/CD4þ gated MMCs were analyzed for the expression of chemokine receptors CCR5, CXCR4, and CCR5/CXCR4 in HIV-uninfected (white boxes), AEI
(light grey boxes), and patients treated for up to 1 y (hatched boxes), 1–3 y (speckled boxes), and 3–7 y (dark grey boxes). In these plots, the boxes
extend from the first to the third quartiles, enclosing the middle 50% of the data. The middle line within each box indicates the median of the data,
whereas the vertical line extends from the 10th to the 90th percentile. Means of the data are represented by filled-in squares.
doi:10.1371/journal.pmed.0040484.g003
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HAART in all groups—1 y treated (34.1% 6 20.2%, p¼ 0.02),
1–3 y treated (27.4% 6 10.7%, p ¼ 0.04), and 3–7 y treated
(29.3% 6 11.6%, p ¼ 0.04) (Figure 4A).
Similar, though less pronounced, results were noted in the
activated memory CD4þ T cell subsets. CD3þCD4þ PBMCs co-
expressing CD45RO/HLA-DR were 5.4% 6 5.0% of the CD4
population in the HIV-uninfected control participants.
During AEI, there was a signiﬁcant increase in this popula-
tion (8.7% 6 6.5%, p¼ 0.04). Post-HAART, activated memory
CD4þ PBMCs approximated HIV-uninfected levels in all
groups (1 y treated group: 4.6% 6 3.2%, p¼ 0.6; 1–3 y treated
group: 5.7%6 6.5%, p¼0.8; and 3–7 y treated group: 4.5% 6
4.4%, p ¼ 0.6). In the GI tract, however, activated memory
CD4þ T cells persisted despite therapy. When compared with
HIV-uninfected CD4þCD45ROþHLA-DRþ MMCs (11.3% 6
5.0%), an increase in activated memory CD4þ T cells that
developed during AEI (29.03% 6 12.1%, p , 0.001) persisted
despite potent antiretroviral therapy in the 1 y treated group
(20.6% 6 10.6%, p¼ 0.007) and 1–3 y treated group (19.2% 6
10.6%, p¼ 0.01), but not in the 3–7 y treated group (18.3% 6
15.2%, p ¼ 0.1) (Figure 4B).
To study a more speciﬁc marker of cellular dynamics, we
examined the expression of Ki67 on GI mucosal CD4þ T cells
and CD8þ T cells by immunohistochemistry (Figure 4C).
Compared with uninfected control participants (3.6% 6
1.6% Ki67þCD4þ T cells and 1.5% 6 1.3% Ki67þCD8þ T
cells), during untreated AEI, a signiﬁcant increase was noted
in the percentage of Ki67þCD4þ T cells (12.4% 6 6.1%, p ,
0.001) and CD8þ T cells (14.2% 6 4.7%, p , 0.001). This
increase persisted in the group treated for 1 y (6.9% 6 3.8%,
Ki67þCD4þ T cells, p , 0.02 and 4.7% 6 3.2% Ki67þCD8þ T
cells, p , 0.02) and 1–3 y (7.3% 6 3.9%, Ki67þCD4þ T cells, p
, 0.007 and 5.1% 6 4.0% Ki67þCD8þ T cells, p , 0.007). In
the 3–7 y treated group, the increase in the percentage of
Ki67þ cells persisted (4.4% 6 1.4% Ki67þCD4þ T cells, p ¼
0.27 and 7.25% 6 4.3% Ki67þCD8þT cells, p¼0.07), although
it was not statistically signiﬁcant.
Thus, while CD4þ and CD8þ lymphocyte activation reverses
with treatment in the peripheral blood, it remains elevated in
the GI tract. In addition, there is a persistent increase in
proliferating CD4þ and CD8þ T cells in the GI tract during
antiretroviral therapy.
Fewer Activated Memory CD8þ T Cells in the GI Tract
during AEI and Posttreatment Correlate with Better
Reconstitution Post–Antiretroviral Therapy
Having established that depletion of CD4þ T cells (and the
CD4:CD8 ratio) in the GI LP persists in the majority of
individuals despite therapy, we sought to identify virological
and immunological factors at baseline and posttreatment that
could account for inter-individual differences. Patients whose
CD4þ T cell numbers reconstituted to HIV-uninfected levels
(Group A, n¼ 9) were compared with patients with persistent
CD4þ T cell depletion in the LP (Group B, n ¼ 21).
With the caveat that patient numbers were relatively
limited, no signiﬁcant differences were noted between groups
A and B with respect to baseline viral load, baseline CD4þ T
cell count, duration of infection prior to biopsy, timing of
initiation of antiretroviral therapy, and duration of therapy
(Table 2). On comparison of immunological parameters
within the GI tract between groups A and B at baseline and
posttreatment (Table 3), we noted that the levels of activated
memory CD8þ T cells were signiﬁcantly higher at baseline
(54.4% 6 17.8%) and posttreatment (29.7% 6 16.2%) in
group B patients than in group A patient at baseline (28.4%
6 6.5%, p ¼ 0.001) and posttreatment (17.2% 6 8.6%, p ¼
0.01), respectively (Table 3). Effector memory (deﬁned as
having a CCR7CD62L phenotype [25]) cells were compared
between groups A and B posttreatment. The levels of
CCR7CD62L CD4þ T cells (90.4% 6 5.4%) and
CCR7CD62L CD8þ T cells (95.9% 6 2.2%) in group A
patients was signiﬁcantly higher than in group B patients
(80.1% 6 12.3% and 91.4% 6 2.5%), respectively (Table 3).
Thus, cell counts in the peripheral blood did not correlate
with mucosal CD4þ T cell reconstitution, whereas local
events, such as the levels of activated memory CD8þ T cells
and effector memory CD4þ T cells and CD8þ T cells within
the GI tract, had a statistically signiﬁcant correlation.
Rare HIV-1 RNA–Expressing Cells Are Detected in
Immune-Inductive and Effector Sites Posttreatment
GI biopsy sections were hybridized using a radiolabeled
probe [18] to detect the presence of viral RNA pre- and
posttreatment. RNA-expressing cells were readily detected in
immune-inductive sites during AEI [11]. In the HAART-
treated patients, rare RNA-expressing cells were detected in
immune-inductive and effector sites (Figure 5). Multiple (4–
28) biopsy sections had to be analyzed in every case to detect
a solitary RNA-expressing cell. At a cellular level, viral RNA
expression was visibly less in antiretroviral therapy–treated
patients compared with AEI-untreated control participants.
Discussion
The present study established that in a majority of patients,
70% of our cohort, CD4þ T cells do not reconstitute in the
LP of the GI tract despite uninterrupted, apparently
suppressive, antiretroviral therapy for up to 5–7 y. Based
on immunohistochemistry, we estimate that approximately
50%–60% of LP CD4þ T cells remain depleted when
compared with HIV-uninfected control participants. CD4þ
T cells expressing the CCR5 receptor or dually expressing the
CCR5/CXCR4 receptors are the cell populations most
severely affected. Accompanying this persistent lesion are
increased levels of activated CD4þ and CD8þ T cells within
the GI tract. In contrast to the degree of CD4þ T cell
depletion, only rare HIV-1 RNA–expressing cells were
detected by in-situ hybridization.
Recent studies of the role of the GI tract have demon-
strated that the CD4þ T cells residing in the LP are selectively
depleted early in the course of acute HIV-1 infection [10–12].
Cross-sectional data on limited numbers of patients suggested
that this lesion persists despite the initiation of HAART
during acute and early infection [11]. To deﬁnitively address
this question, we conducted this study of 40 patients who
began treatment during AEI, to determine whether this lesion
persists during treatment with HAART.
This is, to our knowledge, the largest study describing the
effects of antiretroviral therapy initiated during AEI on CD4þ
T cell reconstitution within the GI tract. Our patients were
closely followed, demonstrated excellent adherence to med-
ication regimen, and maintained undetectable plasma viral
loads for the study duration. Despite this, a majority of our
patients show signiﬁcant mucosal CD4þ T cell depletion. In
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this regard, our results are in contrast to two prior short-term
follow-up studies in HIV-1–infected humans [26] and SIV-
infected macaques [27] which inferred that CD4þ T cell
reconstitution in the GI tract is equivalent to that in
peripheral blood.
It is important to recognize that although ﬂow cytometry
permits the characterization of cellular phenotype for a large
number of cells, the data obtained thus are based on relative
cellular percentages, such that an increase in one cell
population can affect the percentage of the other. To
overcome this potential confounder and to examine absolute
numbers of cells, immunohistochemistry was employed. It is
noteworthy that, while none of the patients examined by ﬂow
cytometry showed ‘‘normalization’’ of CD4þT cell percentage
in the GI tract, 30% of the studied patients did show
‘‘normalization’’ of absolute numbers of CD4þ T cells within
the GI LP. This distinction needs to be taken into consid-
eration so as not to over-interpret suggestions of ‘‘a universal
lack of mucosal reconstitution.’’
Based on the variation in CD4þ T cell reconstitution, we
sought to understand clinical, immunological, and virological
differences between patients. While we did not observe
signiﬁcant clinical differences between the ‘‘reconstitutors’’
and ‘‘non-reconstitutors’’ in terms of baseline plasma viral
loads, peripheral blood CD4þ T cell count, CD4:CD8 ratio,
duration of antiretroviral therapy, or the timing of onset of
antiretroviral therapy, we did observe immunological differ-
ences within the GI tract: the level of activated memory CD8þ
T cells at baseline and posttreatment inversely correlated
with CD4þ T cell reconstitution. In other words, the higher
the level of CD8þ T cell activation, the less likely that
reconstitution would be observed in the GI tract. These data
echo the previously observed inverse correlation between
levels of activated CD8þ T cells, as measured by CD38
expression, and total CD4þ T cell counts in the peripheral
blood [22–24]. We hypothesize that, owing to viral factors,
host factors, or both, the host’s inability to down-regulate
nonspeciﬁc inﬂammatory responses may be one of the
important determinants of the lack of mucosal CD4þ T cell
reconstitution. Perhaps an even larger study could conﬁrm
whether or not correlates of mucosal immune reconstitution
exist among clinical parameters such as plasma viral load,
duration of therapy, and timing of onset of therapy, among
others.
Within the GI tract, there appears to be sub-compartmen-
tal variation: immune-inductive sites reconstitute better than
immune-effector sites and instead resemble peripheral blood
lymphocyte subsets in their reconstitution. It is currently
believed that naı¨ve lymphocytes enter inductive sites through
high endothelial venules expressing mucosal addressin cell
adhesion molecule-1 (MAdCAM-1) interacting with cell sur-
face receptors, particularly a4b7 integrin [28]. Exposure to
cognate antigen activates these lymphocytes, and imprinting
by resident dendritic cells imparts a homing signal so that,
after returning to systemic circulation via the efferent
lymphatic vasculature, gut-activated lymphocytes preferen-
tially home to the LP of the gut to execute their effector
functions [29,30]. Based on this model, we hypothesize that
persistent CD4þ T cell depletion within the effector compart-
ment may be due to reductions in the education of gut-
homing lymphocytes, to altered cellular recruitment or
homing, or to increased cell death due to either ongoing
viral replication and/or immune activation in the effector
compartment.
Memory cells can be classiﬁed on the basis of L-selectin
(CD62L) expression into cells with lymphoid tissue–homing
potential (CD62Lþ) and non-lymphoid tissue–homing poten-
tial (CD62L) [31]. GI lymphocytes fall under the latter
category and express high levels of a4b7 integrin [32].
Krzysiek and coworkers found a signiﬁcant depletion of
blood CD4þ T cells expressing a4b7 integrin during primary
HIV-1 infection and partial recovery following 48 wk of
antiretroviral therapy [33]. Our data examined in this context
would suggest that lack of cellular recruitment to the GI tract
may be one of the factors responsible for persistent mucosal
CD4þ T cell depletion. Indirect support for our hypothesis
was provided by the observation that patients who recon-
stituted CD4þT cells in the GI tract had a signiﬁcantly greater
Figure 4. The Level of Activated and Proliferating CD4þ and CD8þ T Cells Remains Elevated in the GI Tract during HAART
Using four-color flow cytometry, co-expression of CD45RO and HLA-DR was examined on CD3þCD8þ (A) and CD3þCD4þ (B) gated lymphocytes in HIV-
uninfected control participants, AEI, and patients treated for up to 1 y, 1–3 y, and 3–7 y. PBMCs are depicted in white and MMCs in grey boxes.
(C) Using immunohistochemistry, the percentage of GI cells expressing Ki67 was determined on CD4þ T cells (left panel) and CD8þ T cells (right panel).
Levels in HIV-uninfected control participants (white boxes) were compared with AEI (light grey boxes) and patients treated for up to 1 y (hatched
boxes), 1–3 y (speckled boxes), and 3–7 y (dark grey boxes).
In these plots, the boxes extend from the first to the third quartiles, enclosing the middle 50% of the data. The middle line within each box indicates the
median of the data, whereas the vertical line extends from the 10th to the 90th percentile. Means of the data are represented by filled-in squares.
doi:10.1371/journal.pmed.0040484.g004
Table 2. Clinical Comparison between ‘‘Reconstitutors’’ and ‘‘Non-Reconstitutors’’
Baseline Clinical Parameter Group A (‘‘Reconstitutors’’, n ¼ 9) Group B (‘‘Non-Reconstitutors’’, n ¼ 21) p-Value
Infection–biopsy interval (d) 840 6 519 782 6 503 0.1
Infection–treatment interval (d) 77 6 57 54 6 33 0.3
Log10 baseline viral load (copies/ml) 5.7 6 0.9 5.5 6 1.0 0.6
Peripheral blood CD4þ T cell count–baseline (cells/mm3) 384 6 199 446 6 161 0.4
Peripheral blood CD4þ T cell count–posttreatment (cells/mm3) 608 6 283 752 6 221 0.2
Peripheral blood CD8þ T cell count–baseline (cells/mm3) 1,136 6 497 1,010 6 601 0.6
Peripheral blood CD8þ T cell count–posttreatment (cells/mm3) 570 6 178 653 6 191 0.3
Duration of therapy (d) 1134 6 643 743 6 327 0.1
doi:10.1371/journal.pmed.0040484.t002
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percentage of GI effector memory cells (CD62LCCR7)
compared with the ‘‘non-reconstitutors’’ (Table 3). These
data, when examined in conjunction with recent data from
Picker et al. [34], suggest that lack of recruitment of effector
memory cells to mucosal sites may be an important
determinant of local immune reconstitution. Conﬁrmation
of this ﬁnding would be based on analysis of speciﬁc mucosal
homing subsets such as a4b7 integrin—expressing lympho-
cytes. Such analyses were not possible in the present study
because of lack of availability of anti-human a4b7 antibody.
It has been suggested that there may be ongoing viral
replication during antiretroviral therapy [35,36]. Persistent
depletion of mucosal CD4þ T cells expressing CCR5 and
CCR5/CXCR4 (Figure 3), the cells that are targeted during
acute and early infection, may perhaps be a consequence of
HIV-1 associated cytopathicity and/or nonspeciﬁc immune
activation and apoptosis. Increased levels of activated GI
CD4þ and CD8þ T cells, despite normalization in the
peripheral blood (Figure 4A and 4B), could also be indirect
evidence of ongoing viral replication at this site. We were able
to detect rare cells expressing HIV-1 RNA after hybridization
of multiple tissue sections in patients on antiretroviral
treatment (Figure 5). However, the presence of isolated viral
RNA–expressing cells appears discordant to the degree of
CD4þ T cell depletion observed. Low sensitivity of in-situ
hybridization, owing to the relatively small number of cells
that can be examined, may possibly be one of the factors
involved. Further studies using PCR-based techniques are
underway to address this issue.
The consequences of persistent CD4þ T cell depletion in
the GI tract are unknown at this point. It is clear that the
largest reservoir of immune cells [37] shows a unique proﬁle
of CD4þ T cell reconstitution during HAART. In the pre-
HAART era, opportunistic mucosal infections were a
common feature of disease progression. It is evident that,
with treatment, patients do not demonstrate any short-term
effects of having a 50% loss of CD4þ T cells in the GI LP. It is
possible that sufﬁcient redundancy in the immune system
prevents adverse outcome in chronically HIV-1–infected
patients. However, it is important to recognize that, given
the projected long-term survival of HIV-1–infected patients,
signiﬁcant loss of mucosal CD4þ T cells could accelerate
immune senescence with attendant consequences. In recent
clinical studies, an increased incidence of polyps and color-
ectal malignancies has been observed in HIV-1–infected
individuals independent of antiretroviral therapy [38,39].
These studies were conﬁned to a single site and involved a
homogenous cohort of United States veterans. Whether this
ﬁnding can be generalized to other groups remains to be
determined. Therapeutic use of IL-15 to stimulate the
Table 3. Immunological Comparison between ‘‘Reconstitutors’’ and ‘‘Non-Reconstitutors’’
Mucosal Cell Phenotype Group A (‘‘Reconstitutors’’) Group B (‘‘Non-Reconstitutors’’) p-Value
Mean percentage of CD4þ T cells—baseline 23.5 6 5.5 16.8 6 5.1 0.08
Mean percentage of CD4þ T cells—posttreatment 37.8 6 8.1 36.5 6 11.3 0.70
Mean percentage of CD45ROþHLA-DRþ CD4þ T cells—baseline 23.0 6 0.7 28.4 6 15.2 0.30
Mean percentage of CD45ROþHLA-DRþ CD4þ T cells—posttreatment 15.3 6 11.6 19.1 6 9.9 0.40
Mean percentage of CD45ROþHLA-DRþ CD8þ T cells—baseline 28.4 6 6.5 54.4 6 17.8 0.001
Mean percentage of CD45ROþHLA-DRþ CD8þ T cells—posttreatment 17.2 6 8.6 29.7 6 16.2 0.01
Mean percentage of CD62LCCR7 CD4þ T cells—posttreatment 90.4 6 5.4 80.1 6 12.3 0.01
Mean percentage of CD62LCCR7 CD8þ T cells—posttreatment 95.9 6 2.2 91.4 6 5.5 0.05
doi:10.1371/journal.pmed.0040484.t003
Figure 5. Rare HIV-1 RNA–Expressing Cells Were Detected in the GI Tract during HAART
Using a 35S-labeled, single-stranded anti-sense RNA probe of HIV-1, in situ hybridization was performed on paraffin-embedded sections as described in
Methods. Multiple (4–27) sections per patient were examined. Cells were considered positive for viral gene expression if the grain count was more than
six times that of the background. Isolated and rare viral RNA–expressing cells (arrows) were detected in the LP (left panel), T cell zone, and intra-
epithelial lymphocytes (right panel), respectively. Original magnification 503.
doi:10.1371/journal.pmed.0040484.g005
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production of effector memory cells with gut-homing
potential has recently been demonstrated in a nonhuman
primate model [40]. If long-term clinical consequences of
persistent mucosal CD4þ T cell depletion become evident,
modalities such as IL-15 may be considered as adjuncts to
HAART in mucosal immune restoration.
While previous studies have focused on the role of the GI
tract during AEI, the present study establishes that there is a
delay in the majority of patients in mucosal immune
reconstitution despite years of apparently successful antire-
troviral therapy. Taken together, these data highlight the
susceptibility of mucosal sites to HIV-1 and underscore the
critical need to develop better mucosal-protection strategies.
Recent work in the SIV-macaque model has demonstrated
that mucosal delivery of a vaccine may confer better
protection against SIV challenge when compared with
subcutaneous administration of the same vaccine [41]. Other
studies have demonstrated that induction of high-avidity
mucosal cytotoxic T lymphocytes by a mucosally delivered
vaccine delayed the appearance of plasma virus after rectal
SIV challenge in macaques [42]. Similar studies, designed to
test the levels of mucosal protection in humans, are clearly
needed as better HIV-1 vaccines are developed.
Even though we believe this to be the largest study to date
assessing the effect of antiretroviral therapy on the recon-
stitution of CD4þ T cell depletion in the GI tract, there were
inherent limitations in a study of this nature. The patient
population was selected and not random—particularly those
who are willing to undergo repeated biopsy. Furthermore, the
group of control participants was limited in size and was not
matched to the HIV-1–infected study patients. Our study did
not conclusively establish mechanisms of persistent CD4þ T
cell depletion in the GI tract, and we were therefore unable to
deﬁnitively identify factors associated with reconstitution—
an issue that we believe to be important. It is likely that a
larger sample size is needed to address this issue. Finally, the
consequences of the persistence of the identiﬁed lesion
remain obscure. Ongoing research to better understand both
the mechanisms of persistent depletion and its implications is
in progress.
In summary, we have shown that despite the early initiation
of HAART, the marked depletion suffered by the GI mucosal
immune system during acute infection does not completely
reconstitute in the majority of patients. Though not clinically
apparent in the short term, careful observation is warranted
as the long-term consequences of this lesion may become
evident as the HIV-1–infected population ages.
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Editors’ Summary
Background. AIDS causes disease by inactivating the body’s immune
response against infection. The AIDS virus (HIV) is most active against the
white blood cells called T lymphocytes, particularly the CD4 T
lymphocytes, which recognize infection and activate other cells of the
immune system to fight it. In what was formerly believed to be a gradual
process, HIV infection is now known to deplete a subset of the body’s
CD4 lymphocytes, called memory cells, quite rapidly—over only a few
days—within a few weeks after a person becomes infected with the AIDS
virus. This was not known until recently because researchers were
counting CD4 cells only in blood, while a majority of the memory
lymphocytes are located in and around the digestive system. It is these
intestinal memory lymphocytes that are rapidly wiped out, while those in
the blood fall much more gradually, usually over several years. Few
studies of mucosal lymphocytes have been done in humans because
such studies require biopsies of the intestinal lining (mucosa).
Why Was This Study Done? Although CD4 cells in the blood can return
and remain at normal levels when HIV infection is treated with antiviral
drugs, it has been unclear as to whether the mucosal CD4 cells return as
well. People who begin treatment as soon as possible after becoming
infected with HIV might seem to have the best chance of regaining their
mucosal immunity, compared to those who wait until the CD4 cells in
their blood have fallen, which is a generally accepted reason to start
medication for HIV. Therefore, the researchers wanted to see whether
people who start treatment early after becoming infected with HIV
might experience restoration of their mucosal immunity over time and, if
so, what kinds of lymphocytes would return.
What Did the Researchers Do and Find? The researchers studied
people who started treatment for HIV within a few weeks to months of
becoming infected and who then remained on treatment. Some
volunteers underwent biopsies of the intestinal mucosa before starting
treatment and then at various points from 1 y until as long as 3 y after
infection. Others volunteered for biopsy only one time, anywhere from
less than 1 y to 7 y following treatment. The biopsy specimens were
examined under the microscope and with a technique called flow
cytometry using specific staining methods to assess their structure and
functional characteristics. Results were compared to biopsies from a
group of HIV-uninfected volunteers.
The researchers found that the percentage of CD4 lymphocytes
dropped much lower in the intestinal mucosa than in blood during early
infection and then, unlike in blood, remained low even after several years
of treatment for HIV. In the microscope images, they found that mucosal
CD4 cells were lost mostly from regions of active battle against invading
germs, rather than from ‘‘training sites’’ for new CD4 cells. Over time,
only 30% of the volunteers showed return of CD4 cells to normal levels in
these active sites.
Unlike T lymphocytes in the blood, which tend to return to a resting
state after HIV is treated, the T lymphocytes in the intestinal mucosa
tended to persist in an activated state despite HIV treatment, even
though only a tiny fraction of these cells were found to be infected with
HIV. A high level of activation of mucosal lymphocytes soon after
infection was found to predict poor restoration of mucosal CD4 cells over
time.
What Do These Findings Mean? These experiments confirm that
studying easily obtained blood lymphocytes provides only a limited view
of how HIV affects the immune system as a whole. The finding that
immune cells of the intestinal mucosa remain depleted and over-
activated for years despite antiretroviral treatment raises the concern
that over time this will result in clinical problems. Fortunately, this does
not appear to be the case in most people currently being treated for HIV,
some for as long as 10 y, but the results of this study suggest that we
should remain vigilant for gastrointestinal problems resulting from
impaired immunity over time. The finding that mucosal lymphocytes do
appear to return to normal levels in a minority of volunteers is of interest,
and suggests that early interventions to reduce activation of intestinal T
cells (such as antimicrobial or immunomodulatory treatment) might be
worth investigating in those recently infected with HIV. Finally, these
results suggest that a vaccine to prevent HIV may need to stimulate
immune responses that can act very quickly following infection, before
the bulk of lymphocytes capable of countering the infection are lost,
perhaps irreversibly.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040484.g001.
 UCSF HIV InSite includes resources on HIV immunology and vaccine
development
 AIDS fact sheets and brochures from the US National Institute of
Allergy and Infectious Diseases
 Medline Plus article on acute HIV infection from the US National
Library of Medicine
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